Compare SIGA & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIGA | MDWD |
|---|---|---|
| Founded | 1995 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.8M | 202.6M |
| IPO Year | 2016 | 2013 |
| Metric | SIGA | MDWD |
|---|---|---|
| Price | $2.66 | $13.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | ★ 499.5K | 134.5K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | ★ 21.43% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $32.97 |
| Revenue Next Year | $194.92 | $39.75 |
| P/E Ratio | $30.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.66 | $11.80 |
| 52 Week High | $7.11 | $19.70 |
| Indicator | SIGA | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 33.92 | 52.39 |
| Support Level | N/A | $12.16 |
| Resistance Level | $3.43 | $14.52 |
| Average True Range (ATR) | 0.22 | 0.69 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 7.25 | 50.03 |
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.